Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Instructions for authors
  • About the journal
    • About the journal
    • Editorial board
    • Instructions for authors
    • FAQs
    • Chinese Stroke Association
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
Stroke and Vascular Neurology

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Instructions for authors
  • About the journal
    • About the journal
    • Editorial board
    • Instructions for authors
    • FAQs
    • Chinese Stroke Association
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
Open Access

Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)

DOI: 10.1136/svn-2022-001816corr1 Published 25 April 2023
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 8 no. 2 e1
DOI 
https://doi.org/10.1136/svn-2022-001816corr1
PubMed 
36223280

Print ISSN 
2059-8688
Online ISSN 
2059-8696
History 
  • Published online April 25, 2023.

Article Versions

  • Previous version (September 28, 2022 - 06:59).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Author Information

View Full Text

Article usage

Article usage: September 2022 to May 2025

AbstractFullPdf
Sep 202244443
Oct 202210911330
Nov 2022454515
Dec 2022252510
Jan 202319194
Feb 2023575827
Mar 2023464615
Apr 2023858610
May 202314615037
Jun 202319920225
Jul 2023727313
Aug 202310710717
Sep 2023606115
Oct 202346464
Nov 202347479
Dec 2023636415
Jan 202440405
Feb 2024373710
Mar 2024434534
Apr 2024292912
May 202434359
Jun 202426258
Jul 202430277
Aug 202424246
Sep 2024383810
Oct 202426257
Nov 2024775
Apr 20250412
May 202502170

Statistics from Altmetric.com

PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
Stroke and Vascular Neurology: 8 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on Stroke and Vascular Neurology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
(Your Name) has sent you a message from Stroke and Vascular Neurology
(Your Name) thought you would like to see the Stroke and Vascular Neurology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Stroke and Vascular Neurology Apr 2023, 8 (2) e1; DOI: 10.1136/svn-2022-001816corr1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Stroke and Vascular Neurology Apr 2023, 8 (2) e1; DOI: 10.1136/svn-2022-001816corr1
Download PDF

Share
Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Stroke and Vascular Neurology Apr 2023, 8 (2) e1; DOI: 10.1136/svn-2022-001816corr1
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correction: Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial
  • Correction: Rationale and design of Patient-centered Retrospective Observation of Guideline-Recommended Execution for Stroke Sufferers in China: China PROGRESS
Show more Correction

Similar Articles

 
 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • eLetters
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Recommend to librarian
  • Chinese Stroke Association

AUTHORS

  • Instructions for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2025 Chinese Stroke Association